{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:53:04Z","timestamp":1790952784641,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T00:00:00Z","timestamp":1230508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:p>The sodium\u2013glucose co\u2010transporter\u20102 (SGLT2) is a low\u2010affinity transport system that is specifically expressed in the kidney and plays an important role in renal glucose reabsorption in the proximal tubule. Competitive inhibition of SGLT2 therefore represents an innovative therapeutic strategy for the treatment of hyperglycaemia and\/or obesity in patients with type 1 or type 2 diabetes by enhancing glucose and energy loss through the urine. The observation that individuals with familial renal glycosuria maintain normal long\u2010term kidney function provides some reassurance that this mode of action will not adversely affect renal function. Intense research in this therapeutic area has led to the discovery of novel SGLT2 inhibitors, each with different chemical, pharmacodynamic and pharmacokinetic profiles. This review outlines the biology, expression and pleotropic activity of the SGLT system and the pharmacological profile of SGLT2 inhibitors and provides a summary of preclinical and limited clinical data available to characterize the efficacy, safety and potential clinical utility of SGLT2 inhibitors in the management of diabetes.<\/jats:p>","DOI":"10.1111\/j.1463-1326.2008.00982.x","type":"journal-article","created":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T15:02:09Z","timestamp":1230735729000},"page":"79-88","source":"Crossref","is-referenced-by-count":154,"title":["Sodium\u2013glucose co\u2010transporter\u20102 inhibitors: an emerging new class of oral antidiabetic drug"],"prefix":"10.1111","volume":"11","author":[{"given":"Iskandar","family":"Idris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,12,29]]},"reference":[{"key":"e_1_2_7_2_2","article-title":"Analyse des phloridzins","volume":"15","author":"Petersen C","year":"1835","journal-title":"Annales Academie Science Francaise"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1152\/ajplegacy.1903.10.1.67","article-title":"On the action of phlorizin","volume":"10","author":"Stiles PG","year":"1903","journal-title":"Am J Physiol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI100559"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0021-9258(18)70217-2","article-title":"Effect of phlorizin on the osmotic behaviour of mitochondria in isotonic sucrose","volume":"234","author":"Keller DM","year":"1959","journal-title":"J Biol Chem"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3002(62)90543-7"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1016\/S0021-9258(17)32677-7","article-title":"The high affinity Na\/glucose cotransporter. Re\u2010evaluation and distribution of expression","volume":"269","author":"Lee WS","year":"1994","journal-title":"J Biol Chem"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.532"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113157"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112981"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.46.11.1805"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907223410406"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1079\/BJN2002763"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116972"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.51.32678"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.2001.280.1.F10"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10631"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1536-4801.1985.tb08981.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.9.1794"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.140210"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.15.11.1531"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2004.029.05.850959"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.09.038"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2000.7729"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000092790.89332.D2"},{"key":"e_1_2_7_26_2","first-page":"S91","article-title":"Glucose transporters of the glomerulus and the implications for diabetic nephropathy","volume":"60","author":"Heilig CW","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00232-001-0036-y"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2003.046268"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703829"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.110296"},{"issue":"1","key":"e_1_2_7_31_2","article-title":"Metabolic responses to a sodium\u2010glucose transporter\u20102 inhibitor, GW869682, assessed by whole\u2010genome transcript profiling","volume":"50","author":"Ghosh S","year":"2007","journal-title":"Diabetologia"},{"key":"e_1_2_7_32_2","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","author":"Whaley J","year":"2007","journal-title":"Diabetes"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm701272q"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1472"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.140210"},{"issue":"1","key":"e_1_2_7_36_2","article-title":"Remogliflozin etabonate, a potent and selective sodium\u2010dependent glucose transporter 2 antagonist, produced sustained metabolic effects in Zucker Diabetic Fatty rats","volume":"57","author":"Harrington WW","year":"2008","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_7_37_2","article-title":"Long term safety and efficacy of ISIS\u2010388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species","volume":"57","author":"Wancewicz EV","year":"2008","journal-title":"Diabetes"},{"key":"e_1_2_7_38_2","article-title":"Dapagliflozin (BMS\u2010512148), a selective inhibitor of the sodium\u2010glucose uptake transporter 2 (SGLT2), reduces fasting serum glucose and glucose excursion in type 2 diabetes mellitus patients over 14 days","author":"Komoroski B","year":"2007","journal-title":"Diabetes"},{"key":"e_1_2_7_39_2","unstructured":"Bristol Myers\u2010Squibb.Clinical trials disclosure: clinical trials for metabolic disease.http:\/\/ctr.bms.com\/ctd\/InitTrialAction.do?linkname=Metabolics&type=pharma&sortby"},{"issue":"1","key":"e_1_2_7_40_2","article-title":"Efficacy and safety of dapagliflozin in a dose\u2010ranging monotherapy study of treatment\u2010na\u00efve patients with type 2 diabetes","volume":"57","author":"List JF","year":"2008","journal-title":"Diabetes"},{"key":"e_1_2_7_41_2","article-title":"A double\u2010blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy overweight and obese subjects","author":"Hussey EK","year":"2007","journal-title":"Diabetes"},{"issue":"1","key":"e_1_2_7_42_2","article-title":"Clinical studies to assess safety, pharmacokinetics and pharmacodynamics of sergliflozin, a novel inhibitor of glucose reabsorption","volume":"50","author":"Kler L","year":"2007","journal-title":"Diabetologia"},{"key":"e_1_2_7_43_2","article-title":"Dose regimen optimization for a novel therapeutic drug (SGLT inhibitor) using a physiological pharmacokinetic\u2010pharmacodynamic model incorporating both human and in\u2010vitro data","author":"O\u2019Connor\u2010Semmes RL","year":"2007","journal-title":"Diabetes"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1375.058"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.2337\/db06-0376"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01594.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.12.1737"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(75)90028-0"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.9.1763"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-004-0633-9"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-0102(95)00876-U"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90101-K"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1006\/nlme.1998.3856"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/019021499270150"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2008.00982.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2008.00982.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:20:58Z","timestamp":1761866458000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2008.00982.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,29]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1463-1326.2008.00982.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2008.00982.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,29]]}}}